RELMADA THERAPEUTICS, INC.
RLMDNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for RLMD. That does not mean none is planned.
Get an email about RLMD's next catalysts
Track RELMADA THERAPEUTICS (RLMD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
RLMD Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.14 | FQ end Sep/2026 | Call: amc
Market Overview
Stock performance and key metrics
REL-1017
Depressive Disorder, Major
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Non Muscle Invasive Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
REL-1017 | Phase 3 | Depressive Disorder, Major | - | - |
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel | Phase 2 | Non Muscle Invasive Bladder Cancer | - | - |
Frequently asked questions
What is in RELMADA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in RELMADA THERAPEUTICS, INC.'s (RLMD) pipeline across Phase 3, Phase 2. Its lead program is REL-1017 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is RELMADA THERAPEUTICS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for RELMADA THERAPEUTICS, INC. (RLMD) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RLMD biotech catalysts?→
Add RLMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow RELMADA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.